<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490982</url>
  </required_header>
  <id_info>
    <org_study_id>CE15.016</org_study_id>
    <nct_id>NCT02490982</nct_id>
  </id_info>
  <brief_title>Teriflunomide Observational Effectiveness Study</brief_title>
  <official_title>Teriflunomide Observational Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montreal Neurological Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this investigator-initiated study is to evaluate the effectiveness and
      efficacy of Teriflunomide in a population of Relapsing Remitting Multiple Sclerosis (RRMS)
      patients treated in regular practice, over a period of at least two years, in the regular
      setting of a Multiple Sclerosis Clinic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting adult RRMS patients, meeting all inclusion criteria and who have been prescribed
      Teriflunomide by their treating physician will be asked to complete questionnaires on quality
      of life (QoL), fatigue, and employment.

      The study will include 300 participants from three Multiple Sclerosis (MS) Clinics. Disease
      and magnetic resonance imaging (MRI) activity, blood tests (aspartate aminotransferase (AST),
      alanine aminotransferase (ALT), complete blood count (CBC)), drug compliance, side effects,
      toxicity, will be monitored.

      MS patients never treated with a disease modifying drug (DMD) and MS patients previously
      exposed to another DMD will be included. Some would have been on a single medication, while
      others would have been treated with two or more medications.

      The results of the study will provide the patient-perceived global impacts of Teriflunomide
      on the patient's overall quality of life.

      These results will also guide the physician in giving a treatment that will be adapted to the
      patient's major concerns.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported outcome (PRO) scores</measure>
    <time_frame>one year</time_frame>
    <description>Change on patient-reported outcome measures, from baseline score and at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity - Composite measure</measure>
    <time_frame>one year</time_frame>
    <description>Change in the annualized relapse-rate and the Expanded Disability Status Scale (EDSS) over the two year period.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Teriflunomide</arm_group_label>
    <description>Patient-reported outcomes and clinical assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide</intervention_name>
    <description>The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.</description>
    <arm_group_label>Teriflunomide</arm_group_label>
    <other_name>Aubagio</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Relapsing Remitting Multiple Sclerosis patients followed at three MS Clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting Relapsing Remitting Multiple Sclerosis adults with an Expanded Disability
             Status Scale (EDSS) score ≤ 5.0 who have been prescribed Teriflunomide and who agree
             to follow study procedures.

        Exclusion Criteria:

          -  Primary progressive or secondary progressive Multiple Sclerosis without relapses;
             other diseases that may confound evaluation of outcomes; other exclusion as per
             product monograph; and women contemplating pregnancy or actually pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Duquette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.</citation>
    <PMID>21991951</PMID>
  </reference>
  <reference>
    <citation>Rush AJ. The role of efficacy and effectiveness trials. World Psychiatry. 2009 Feb;8(1):34-5.</citation>
    <PMID>19293957</PMID>
  </reference>
  <reference>
    <citation>Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011 Oct;2(4):137-44. doi: 10.4103/2229-3485.86879.</citation>
    <PMID>22145124</PMID>
  </reference>
  <reference>
    <citation>Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013 Aug 1;369(5):397-400. doi: 10.1056/NEJMp1114649. Epub 2013 Jul 3.</citation>
    <PMID>23822654</PMID>
  </reference>
  <reference>
    <citation>Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler. 2003 Feb;9(1):63-72. Review.</citation>
    <PMID>12617271</PMID>
  </reference>
  <reference>
    <citation>Teriflunomide (Aubagio) (14 mg Film-coated Tablet): Teriflunomide is Indicated as Monotherapy for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis to Reduce the Frequency of Clinical Exacerbations and to Delay the Accumulation of Physical Disability [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK253634/</citation>
    <PMID>25411660</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</investigator_affiliation>
    <investigator_full_name>Pierre Duquette</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

